On Mar. 3, a press release triggered a massive spike in Inovio stock. The company detailed its plan to accelerate the time for its COVID-19 vaccine. The new plan was to begin human trials in April, and to have one million doses of the vaccine available by the end of the year. In response, INO rocketed to $14.09 within days, a 221% gain.